Extracorporeal Blood Purification Can Cut Cardiac Surgery-Associated AKI
By Elana Gotkine HealthDay Reporter
FRIDAY, Oct. 11, 2024 -- For patients undergoing nonemergent cardiopulmonary bypass (CPB), use of an extracorporeal blood purification (EBP) device is associated with a lower rate of cardiac surgery-associated acute kidney injury (CSA-AKI), according to a study published online Oct. 9 in the Journal of the American Medical Association to coincide with the annual congress of the European Society of Intensive Care Medicine, held from Oct. 5 to 9 in Barcelona, Spain.
Xosé Pérez-Fernández, Ph.D., from L'Hospitalet de Llobregat in Barcelona, Spain, and colleagues conducted a double-blind, randomized clinical trial in two tertiary hospitals to examine whether use of an EBP device reduces CSA-AKI after CPB. Adults undergoing nonemergent cardiac surgery who were at high risk for CSA-AKI were randomly assigned to receive EBP or standard care (169 and 174 patients, respectively).
The researchers found that the rate of CSA-AKI was 28.4 and 39.7 percent in the EBP and standard-care groups, respectively. In most of the predefined clinical secondary end points or post hoc exploratory end points, there were no significant differences observed. In terms of CSA-AKI reduction, EBP was more effective for patients with chronic kidney disease, diabetes, hypertension, low left ventricular ejection fraction (<40 percent), and lower body mass index (<30 kg/m2) in a sensitivity analysis. The groups did not differ in adverse events.
"The use of a nonselective EBP device connected to the CPB circuit in a nonemergent population of patients undergoing cardiac surgery was associated with a significant reduction of CSA-AKI in the first seven days after the surgical procedure," the authors write.
One author disclosed ties to Exthera and SphingoTec.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
ASCO: Durvalumab Plus FLOT Beneficial for Resectable Gastric, GE Junction Cancer
THURSDAY, June 5, 2025 -- For patients with resectable gastric or gastroesophageal junction adenocarcinoma, durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel...
Endolymphatic Sac Decompression Effective for Vertigo, Migraine
WEDNESDAY, May 28, 2025 -- For Meniere disease (MD) patients with migraine, endolymphatic sac decompression (ELSD) is effective, providing postoperative relief of vertigo and...
One-Week Radiotherapy for Breast Cancer Safe, Effective Up to 10 Years
TUESDAY, May 27, 2025 -- A five-fraction, one-week schedule of adjuvant breast radiotherapy is as safe and effective as a standard three-week schedule for patients with invasive...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.